In the last trading session, 1.24 million shares of the Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) were traded, and its beta was 1.55. Most recently the company’s share price was $16.33, and it changed around $1.29 or 8.58% from the last close, which brings the market valuation of the company to $2.15B. CNTA currently trades at a discount to its 52-week high of $19.09, offering almost -16.9% off that amount. The share price’s 52-week low was $7.75, which indicates that the current value has risen by an impressive 52.54% since then.
Centessa Pharmaceuticals plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CNTA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Centessa Pharmaceuticals plc ADR is expected to report earnings per share of -0.35 for the current quarter.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Instantly CNTA has showed a green trend with a performance of 8.58% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 16.44 on recent trading dayincreased the stock’s daily price by 0.67%. The company’s shares are currently down -2.51% year-to-date, but still up 3.68% over the last five days. On the other hand, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is -3.49% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to increase their stock price by 29.0% from its current value. Analyst projections state that CNTA is forecast to be at a low of $19 and a high of $28.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Centessa Pharmaceuticals plc ADR earnings are expected to increase by 2.97% in 2025, but the outlook is negative -3.20% per year for the next five years.
CNTA Dividends
Centessa Pharmaceuticals plc ADR’s next quarterly earnings report is expected to be released in April.
GENERAL ATLANTIC, L.P., with 8.8427% or 9.68 million shares worth $87.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Price (T.Rowe) Health Sciences Fund and Fidelity Select Portfolios – Biotechnology were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.48 shares worth $56.77 million, making up 2.64% of all outstanding shares. On the other hand, Fidelity Select Portfolios – Biotechnology held roughly 2.98 shares worth around $48.61 million, which represents about 2.26% of the total shares outstanding.
